The FDA issued an advisory notice that serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh benefits for patients with sinusitis, bronchitis and uncomplicated urinary tract infections who have other treatment options, recommending that a fluoroquinolone should be used to treat these conditions only when patients have no therapeutic alternatives.